{"entity":{"id":"nct06459687","kind":"trial","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","aka":[],"tldr":"A phase 3 trial of Socazolimab run by Lee's Pharmaceutical Limited in cervical cancer, now recruiting.","summary":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06459687 by Lee's Pharmaceutical Limited, with 440 participants planned, started 2024-11-28. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06459687","url":"https://clinicaltrials.gov/study/NCT06459687"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["socazolimab"],"companies":["lees-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06459687","phase":"3","setting":"Efficacy and Safety of Socazolimab Combined With Chemotherapy With or Without Bevacizumab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer: A Randomized, Double-blind, Placebo-controlled Phase III Study","sponsor":"Lee's Pharmaceutical Limited","enrolled":440,"outcomes":[]},"route":"/trials/nct06459687/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"drug":[{"id":"socazolimab","kind":"drug","name":"Socazolimab","route":"/drugs/socazolimab/"}],"company":[{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","route":"/companies/lees-pharmaceutical/"}]}}